1. Search Result
Search Result
Isoforms Recommended: VEGFR1/Flt-1
Results for "

Flt-1

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

1

Natural
Products

8

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101219

    VEGFR c-Kit EGFR Cancer
    VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively [1].
    VEGFR-IN-1
  • HY-P99364

    Anti-VEGFR1/Flt1 Reference Antibody; IMC-18F1

    VEGFR Cancer
    Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors [1].
    Icrucumab
  • HY-10517
    Orantinib
    5 Publications Verification

    SU6668; TSU-68

    PDGFR FGFR VEGFR Apoptosis Cancer
    Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.
    Orantinib
  • HY-P99830

    KH902

    VEGFR Others
    Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc [1].
    Conbercept
  • HY-13049
    Cediranib maleate
    5+ Cited Publications

    AZD-2171 maleate

    VEGFR Autophagy PDGFR Cancer
    Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
    Cediranib maleate
  • HY-10205
    Cediranib
    5+ Cited Publications

    AZD2171

    VEGFR Autophagy PDGFR Cancer
    Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
    Cediranib
  • HY-RS04987

    Small Interfering RNA (siRNA) Others

    FLT1 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FLT1 Human Pre-designed siRNA Set A
    FLT1 Human Pre-designed siRNA Set A
  • HY-RS04988

    Small Interfering RNA (siRNA) Others

    Flt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Flt1 Mouse Pre-designed siRNA Set A
    Flt1 Mouse Pre-designed siRNA Set A
  • HY-RS04989

    Small Interfering RNA (siRNA) Others

    Flt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Flt1 Rat Pre-designed siRNA Set A
    Flt1 Rat Pre-designed siRNA Set A
  • HY-110272

    PTK787 succinate; ZK-222584 succinate; CGP-79787 succinate

    VEGFR Cancer
    Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively [1].
    Vatalanib succinate
  • HY-10204
    OSI-930
    4 Publications Verification

    c-Kit VEGFR c-Fms Apoptosis Cancer
    OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity [1].
    OSI-930
  • HY-10205R

    VEGFR Autophagy PDGFR Cancer
    Cediranib (Standard) is the analytical standard of Cediranib. This product is intended for research and analytical applications. Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
    Cediranib (Standard)
  • HY-168114

    FLT3 PDGFR VEGFR Cancer
    Multi-kinase inhibitor 3 (compound 12) is a potent and orally active multikinase inhibitor with IC50 values of 1.59, 1.23, 1.19, 0.59, 0.22, 1.15 nM for FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, PDGFRβ, respectively. Multi-kinase inhibitor 3 shows antiproliferative activity. Multi-kinase inhibitor 3 shows anticancer activity [1].
    Multi-kinase inhibitor 3
  • HY-168115

    FLT3 PDGFR Cancer
    Multi-kinase inhibitor 4 (compound 14) is an orally active inhibitor of FLT1, KDR, FLT3, FLT4, PDGFRα, PDGFRβ, with IC50s of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, 0.89 nM. Multi-kinase inhibitor 4 plays an important role in cancer research [1].
    Multi-kinase inhibitor 4
  • HY-15813

    FGFR irreversible inhibitor-1

    FGFR Cancer
    FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively [1].
    FIIN-1
  • HY-145293

    DAPK Cancer
    TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC50 of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC50=0.030 μM), Flt1 (IC50=0.191 μM) and DRAK1 (IC50=0.411 μM). TNIK-IN-3 can be used for the research of colorectal cancer [1].
    TNIK-IN-3
  • HY-50751G

    ABT-869; AL-39324

    VEGFR PDGFR Cancer
    Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells [1].
    Linifanib
  • HY-50751
    Linifanib
    4 Publications Verification

    ABT-869; AL-39324

    PDGFR VEGFR FLT3 c-Fms c-Kit Autophagy Apoptosis Cancer
    Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis [1] .
    Linifanib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: